EL Stock Analysis: EssilorLuxottica S. A. | PA
Medical Instruments & Supplies | PA, France | Market Cap: 78.728m EUR | 12M Return: -29.9% | FR0000121667 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 109M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
EssilorLuxottica S.A. (EL) is a Paris-headquartered company, founded in 1849 and reorganized under its current name in October 2018 following the combination of lens maker Essilor and eyewear manufacturer Luxottica. The group designs, manufactures, and globally distributes ophthalmic lenses, frames, sunglasses, contact lenses, and a wide range of optician instruments and diagnostic equipment, operating across North America, Europe, the Middle East and Africa, Latin America, and Asia-Pacific.
Its portfolio spans both healthcare-oriented and consumer-facing eyewear brands, including Varilux, Crizal, Stellest, and Transitions on the lens side, and Ray-Ban, Oakley, Persol, Oliver Peoples, and Vogue Eyewear in fashion frames. Through brands such as Satisloh and the SPECTRALIS imaging platform, it also supplies eye-care professionals with refraction, edging, finishing, and diagnostic hardware, making the business one of the few players that is vertically integrated from lens and frame manufacturing through to retail distribution.
Distribution reaches independent opticians, third-party e-commerce platforms, and large retail chains, alongside the companys own brick-and-mortar stores and online channels. The eyewear industry is unusual in straddling health care (corrective lenses, diagnostics, optical instruments) and consumer discretionary (fashion sunglasses, branded frames), which is reflected in EssilorLuxotticas positioning as both a health care equipment supplier and a major branded eyewear retailer.
- Ray-Ban Meta smart glasses accelerate wearables revenue growth
- Retail vertical integration through LensCrafters and Sunglass Hut boosts operating margins
- Europe and China consumer softness pressures reported revenue growth
| Net Income: 2.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.48 > 1.0 |
| NWC/Revenue: -4.80% < 20% (prev -1.32%; Δ -3.48% < -1%) |
| CFO/TA 0.08 > 3% & CFO 5.29b > Net Income 2.49b |
| Net Debt (17.3b) to EBITDA (6.78b): 2.55 < 3 |
| Current Ratio: 0.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (464.4m) vs 12m ago 1.27% < -2% |
| Gross Margin: 60.84% > 18% (prev 62.44%; Δ -1.60% > 0.5%) |
| Asset Turnover: 46.12% > 50% (prev 43.99%; Δ 2.13% > 0%) |
| Interest Coverage Ratio: 10.20 > 6 (EBIT TTM 3.62b / Interest Expense TTM 355.0m) |
| A: -0.02 (Total Current Assets 11.2b - Total Current Liabilities 12.6b) / Total Assets 65.1b |
| B: 0.26 (Retained Earnings 16.6b / Total Assets 65.1b) |
| C: 0.06 (EBIT TTM 3.62b / Avg Total Assets 63.5b) |
| D: 1.56 (Book Value of Equity 39.2b / Total Liabilities 25.1b) |
| Altman-Z'' = 2.71 = A |
| DSRI: 0.93 (Receivables 3.99b/4.01b, Revenue 29.3b/27.2b) |
| GMI: 1.03 (GM 62.44% / 60.84%) |
| AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 29.3b / 27.2b) |
| TATA: -0.04 (NI 2.49b - CFO 5.29b) / TA 65.1b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of August 10, 2026, the stock is trading at EUR 172.30 with a total of 786,218 shares traded. Over the past week, the price has changed by +5.03%, over one month by +0.38%, over three months by +3.17% and over the past year by -29.93%.
Current recommended Stop Loss: 165.20 (which is 4.1% or 1.3 ATR below the current price).
EssilorLuxottica S. A. has no consensus analysts rating.
P/E Trailing = 32.0187
P/E Forward = 22.4719
P/S = 2.6883
P/B = 1.9876
P/EG = 1.7031
Revenue TTM = 29.3b EUR
EBIT TTM = 3.62b EUR
EBITDA TTM = 6.78b EUR
Long Term Debt = 6.73b EUR (from longTermDebt, last quarter)
Short Term Debt = 5.66b EUR (from shortTermDebt, last quarter)
Debt = 19.2b EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.91b
Net Debt = 17.3b EUR (calculated: Debt 19.2b - CCE 1.93b)
Enterprise Value = 96.0b EUR (78.7b + Debt 19.2b - CCE 1.93b)
Interest Coverage Ratio = 10.20 (Ebit TTM 3.62b / Interest Expense TTM 355.0m)
EV/FCF = 24.99x (Enterprise Value 96.0b / FCF TTM 3.84b)
FCF Yield = 4.00% (FCF TTM 3.84b / Enterprise Value 96.0b)
FCF Margin = 13.12% (FCF TTM 3.84b / Revenue TTM 29.3b)
Net Margin = 8.52% (Net Income TTM 2.49b / Revenue TTM 29.3b)
Gross Margin = 60.84% ((Revenue TTM 29.3b - Cost of Revenue TTM 11.5b) / Revenue TTM)
Gross Margin QoQ = 63.47% (prev 58.15%)
Tobins Q-Ratio = 1.48 (Enterprise Value 96.0b / Total Assets 65.1b)
Interest Expense / Debt = 1.85% (Interest Expense 355.0m / Debt 19.2b)
Taxrate = 23.99% (831.0m / 3.46b)
NOPAT = 2.75b (EBIT 3.62b * (1 - 23.99%))
Current Ratio = 0.89 (Total Current Assets 11.2b / Total Current Liabilities 12.6b)
Debt / Equity = 0.49 (Debt 19.2b / totalStockholderEquity, last quarter 39.2b)
Debt / EBITDA = 2.55 (Net Debt 17.3b / EBITDA 6.78b)
Debt / FCF = 4.50 (Net Debt 17.3b / FCF TTM 3.84b)
Total Stockholder Equity = 39.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.93% (Net Income 2.49b / Total Assets 65.1b)
RoE = 6.38% (Net Income TTM 2.49b / Total Stockholder Equity 39.1b)
RoCE = 7.90% (EBIT 3.62b / Capital Employed (Equity 39.1b + L.T.Debt 6.73b))
RoIC = 4.86% (NOPAT 2.75b / Invested Capital 56.6b)
WACC = 6.22% (E(78.7b)/V(98.0b) * Re(7.40%) + D(19.2b)/V(98.0b) * Rd(1.85%) * (1-Tc(0.24)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.34 | Cagr: 1.87%
[DCF] Terminal Value 77.85% ; FCFF base≈3.65b ; Y1≈4.16b ; Y5≈6.02b
[DCF] Fair Price = 159.8 (EV 90.7b - Net Debt 17.3b = Equity 73.4b / Shares 459.6m; r=8.35% [WACC [floored]]; 5y FCF grow 14.24% → 2.50% )
EPS Correlation: -54.48 | EPS CAGR: -0.99% | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.09 | Revenue CAGR: 6.08% | SUE: 1.23 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=7.40 | Chg30d=+2.38% | Revisions=-56% | GrowthEPS=+9.0% | GrowthRev=+6.5%
EPS next Year (2027-12-31): EPS=8.12 | Chg30d=-0.30% | Revisions=-81% | GrowthEPS=+9.6% | GrowthRev=+9.1%
[Analyst] Revisions Ratio: -76% (up=2, down=24)